Momenta Pharmaceuticals, Inc. (MNTA)

[hptaxis]

Personally, I like MNTA for its IP, as well as mL and possible mC and other FOB. But, none of this is evident by no pipeline. The cash flow for being the sole generic on mL is now completely end entirely busted. I believe there was discussion that should there be another entrant for L, an authorized generic is likely.

By splitting the market four ways, NVS share is about $250 Million. Of this, MNTA will get around <<$50 Million (is this correct). Without taking into account the cash on hand, a P/E of ~10-15 put the PPS below $10, maybe $8. Right now, I think the cash on hand is holding up a considerable part of the PPS. JMHO [I think MNTA's valuation is far too low.]